EP4387998A4 - ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AGAINST CD155 AND METHOD FOR USE THEM - Google Patents

ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AGAINST CD155 AND METHOD FOR USE THEM

Info

Publication number: EP4387998A4
Authority: EP; European Patent Office
Prior art keywords: antigen; antibodies; binding fragments; fragments against; binding
Prior art date: 2021-08-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21954398.0A

Other languages

German (de)

French (fr)

Other versions

EP4387998A1 (en

Inventor

Aftab S Karim

Robert Holgate

Arron Hearn

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tasrif Pharmaceutical LLC

Original Assignee

Tasrif Pharmaceutical LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-08-20

Filing date

2021-08-20

Publication date

2026-01-28

2021-08-20 Application filed by Tasrif Pharmaceutical LLC filed Critical Tasrif Pharmaceutical LLC

2024-06-26 Publication of EP4387998A1 publication Critical patent/EP4387998A1/en

2026-01-28 Publication of EP4387998A4 publication Critical patent/EP4387998A4/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP21954398.0A 2021-08-20 2021-08-20 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AGAINST CD155 AND METHOD FOR USE THEM Pending EP4387998A4 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2021/046855 WO2023022729A1 (en)	2021-08-20	2021-08-20	Antibodies and antigen binding fragments against cd155 methods of use thereof

Publications (2)

Publication Number	Publication Date
EP4387998A1 EP4387998A1 (en)	2024-06-26
EP4387998A4 true EP4387998A4 (en)	2026-01-28

Family

ID=85239697

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21954398.0A Pending EP4387998A4 (en)	2021-08-20	2021-08-20	ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AGAINST CD155 AND METHOD FOR USE THEM

Country Status (6)

Country	Link
EP (1)	EP4387998A4 (en)
JP (1)	JP2024531426A (en)
CN (1)	CN118302445A (en)
AU (1)	AU2021460932A1 (en)
CA (1)	CA3229327A1 (en)
WO (1)	WO2023022729A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2025092966A1 (en) *	2023-11-02	2025-05-08	重庆精准生物技术有限公司	Specific tigit peptide fragment
CN119431583B (en) *	2024-12-19	2025-09-30	重庆国际免疫创新中心有限公司	Antibodies or antigen-binding fragments targeting CD155 and their applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004074324A2 (en) *	2003-02-24	2004-09-02	Xerion Pharmaceuticals Ag	Modulation of the poliovirus receptor function
WO2021070181A1 (en) *	2019-10-08	2021-04-15	Nectin Therapeutics Ltd.	Antibodies against the poliovirus receptor (pvr) and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6518033B1 (en) *	1998-08-05	2003-02-11	The Research Foundation Of State University Of New York	Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
US20100291071A1 (en) *	2008-08-01	2010-11-18	Immunas Pharma, Inc.	Antibody Specific Binding to A-Beta Oligomer and the Use
US9926377B2 (en) *	2014-05-22	2018-03-27	Genentech, Inc.	Anti-GPC3 antibodies and immunoconjugates
AU2015279316B2 (en) *	2014-06-27	2021-03-04	Innate Pharma	Multispecific NKp46 binding proteins
JP5995117B2 (en) *	2015-01-26	2016-09-21	国立大学法人筑波大学	Method for detecting cancer using soluble CD155 protein
WO2017046746A1 (en) *	2015-09-15	2017-03-23	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
CN117069841A (en) *	2015-10-06	2023-11-17	艾利妥	anti-TREM 2 antibodies and methods of use thereof
WO2017149538A1 (en) *	2016-03-01	2017-09-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Antibodies specific to human poliovirus receptor (pvr)

2021
- 2021-08-20 EP EP21954398.0A patent/EP4387998A4/en active Pending
- 2021-08-20 CA CA3229327A patent/CA3229327A1/en active Pending
- 2021-08-20 AU AU2021460932A patent/AU2021460932A1/en active Pending
- 2021-08-20 WO PCT/US2021/046855 patent/WO2023022729A1/en not_active Ceased
- 2021-08-20 CN CN202180103365.5A patent/CN118302445A/en active Pending
- 2021-08-20 JP JP2024510508A patent/JP2024531426A/en active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004074324A2 (en) *	2003-02-24	2004-09-02	Xerion Pharmaceuticals Ag	Modulation of the poliovirus receptor function
WO2021070181A1 (en) *	2019-10-08	2021-04-15	Nectin Therapeutics Ltd.	Antibodies against the poliovirus receptor (pvr) and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOBIS P. ET AL: "Production of a Monoclonal Antibody against an Epitope on HeLa Cells that Is the Functional Poliovirus Binding Site", JOURNAL OF GENERAL VIROLOGY, vol. 66, no. 12, 1 December 1985 (1985-12-01), pages 2563 - 2569, XP093267104, ISSN: 0022-1317, DOI: 10.1099/0022-1317-66-12-2563 *
See also references of WO2023022729A1 *

Also Published As

Publication number	Publication date
JP2024531426A (en)	2024-08-29
EP4387998A1 (en)	2024-06-26
CN118302445A (en)	2024-07-05
AU2021460932A1 (en)	2024-03-07
WO2023022729A1 (en)	2023-02-23
CA3229327A1 (en)	2023-02-23

Publication	Publication Date	Title
EP4225373A4 (en)	2025-01-08	ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
EP3755690A4 (en)	2021-10-27	EGFR INHIBITORS AND METHOD OF USE THEREOF
EP4007605A4 (en)	2023-08-16	FCRN ANTIBODIES AND METHODS OF USE THEREOF
EP4291578A4 (en)	2025-04-02	ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF
EP4021498A4 (en)	2024-01-03	CROSS-SPECIES ANTI-LATENT TGF-BETA-1 ANTIBODIES AND METHOD OF USE
EP4090685A4 (en)	2024-12-18	ANTI-GAL3 ANTIBODIES AND METHODS OF USE
EP4240417A4 (en)	2024-10-02	FCRN ANTIBODIES AND METHODS OF USE THEREOF
EP4401764A4 (en)	2025-11-05	ANTI-SIGLEC-6 ANTIBODIES AND METHOD FOR USE THEM
EP4061848A4 (en)	2024-03-20	ANTI-ROR-2 ANTIBODIES AND METHOD OF USE
EP3870613A4 (en)	2022-08-03	ALK2 ANTIBODIES AND METHODS OF USE THEREOF
EP3994174A4 (en)	2024-05-22	MONOSPECIFIC ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE
EP3574010A4 (en)	2020-12-16	ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
EP3579860A4 (en)	2020-12-09	TRAILSHORT ANTIBODIES AND METHOD OF USE
EP4320164A4 (en)	2025-07-16	BISPECIFIC ANTIBODIES AGAINST NKP46 AND CD38 AND METHODS OF USE THEREOF
EP4412617A4 (en)	2025-12-24	Novel Pikfyve inhibitors and methods for using them
EP4399230A4 (en)	2025-12-03	CHIMERIC ANTI-GPC3 ANTIGEN RECEPTOR AND METHOD FOR USE THEREA
EP4387998A4 (en)	2026-01-28	ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AGAINST CD155 AND METHOD FOR USE THEM
EP3987030A4 (en)	2023-10-18	PPM1A INHIBITORS AND METHODS OF USE THEREOF
EP3755697A4 (en)	2021-10-27	EGFR DEGRADER AND METHOD OF USE THEREOF
EP4159454A4 (en)	2024-06-26	ELEMENT FOR DETERMINING AUTHENTICITY AND METHOD FOR DETERMINING AUTHENTICITY THEREOF
EP4466293A4 (en)	2026-02-18	PROTEIN COMPLEX AGAINST CD47/PD-L1 AND METHOD FOR USE THEREMISH
EP4333893A4 (en)	2025-06-18	ANTI-TIGIT ANTIBODIES, ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOF
EP4392448A4 (en)	2025-09-24	PILRA ANTIBODIES AND METHODS OF USE THEREOF
EP4412661A4 (en)	2025-11-12	ANTI-TROP2 ANTIBODY COMBINATION THERAPIES AND METHODS FOR USE THEM
EP4341299A4 (en)	2026-01-14	ANTI-CEA ANTIBODIES AND METHOD OF USE

Legal Events

Date	Code	Title	Description
2023-02-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2024-05-24	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2024-05-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2024-06-26	17P	Request for examination filed	Effective date: 20240319
2024-06-26	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-11-27	DAV	Request for validation of the european patent (deleted)
2024-11-27	DAX	Request for extension of the european patent (deleted)
2025-09-17	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101AFI20250813BHEP Ipc: C07K 16/08 20060101ALI20250813BHEP Ipc: A61K 39/42 20060101ALI20250813BHEP Ipc: A61P 35/00 20060101ALI20250813BHEP
2026-01-28	A4	Supplementary search report drawn up and despatched	Effective date: 20260107
2026-01-28	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101AFI20251222BHEP Ipc: C07K 16/08 20060101ALI20251222BHEP Ipc: A61K 39/42 20060101ALI20251222BHEP Ipc: A61P 35/00 20060101ALI20251222BHEP